Merck signs $400 million deal with China’s SciBrunch for KRAS G12D preclinical candidate

Sep 28, 2026read at Fierce Biotech ↗DealNeutral

Merck & Co. announced a new partnership with Chinese biotech SciBrunch. The agreement includes a $400 million payment for a preclinical candidate that targets the KRAS G12D mutation.

The KRAS G12D mutation is a recognized driver in several types of cancer, and the candidate is intended to expand Merck's oncology pipeline.

This deal places Merck among several pharma companies that are actively pursuing KRAS G12D therapies through external collaborations.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D”

read at Fierce Biotech ↗

414 words · retrieved 12m ago

sharex / twitter linkedin

Merck signs $400 million deal with China’s SciBrunch for KRAS G12D preclinical candidate

comments(0)

Merck signs $400 million deal with China’s SciBrunch for KRAS G12D preclinical candidate

comments(0)